West, Nathaniel R http://orcid.org/0000-0001-9991-0503
,
Hegazy, Ahmed N
Owens, Benjamin M J
Bullers, Samuel J
Linggi, Bryan
Buonocore, Sofia
Coccia, Margherita
Görtz, Dieter
This, Sébastien
Stockenhuber, Krista
Pott, Johanna
Friedrich, Matthias
Ryzhakov, Grigory
Baribaud, Frédéric
Brodmerkel, Carrie
Cieluch, Constanze
Rahman, Nahid
Müller-Newen, Gerhard
Owens, Raymond J
Kühl, Anja A
Maloy, Kevin J
Plevy, Scott E
Keshav, Satish
Travis, Simon P L http://orcid.org/0000-0002-2690-4361
Powrie, Fiona
Article History
Received: 23 December 2016
Accepted: 17 February 2017
First Online: 3 April 2017
Change Date: 11 April 2017
Change Type: Erratum
Change Details: In the version of this article initially published, there were two typographical errors in the Abstract. The unnecessary ‘h’ in the line “Furthermore, h according to…..” has been deleted. The line “OSM is thus a potential biomarker of and therapeutic target for IBD,….” was changed to read “OSM is thus a potential biomarker and therapeutic target for IBD…”. These errors have been corrected in the HTML and PDF versions of the article. A coding error that inadvertently resulted in incorrect ordering of the authors in the HTML version was also corrected.
Competing interests
: N.R.W., A.N.H., B.M.J.O., and F.P. are inventors of patents relating to OSM as a therapeutic target for IBD. S.K. has received honoraria and/or research support from Allergan, Abbvie, Astra-Zeneca, ChemoCentryx Inc., Dr Falk Pharma, Ferring, Gilead, GSK, Merck, Mitsubishi-Tanabe Pharma, Pfizer, and Vifor Pharma. S.P.L.T. has received research support from Abbvie, IOIBD, Lilly, UCB, Vifor, and the Norman Collison Foundation. S.P.L.T. receives consulting fees from Abbvie, Amgen, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Chemocentryx, Cosmo, Ferring, Giuliani SpA, GSK, Lilly, MSD, Neovacs, NovoNordisk, Norman Collison Foundation, Novartis, NPS Pharmaceuticals, Pfizer, Proximagen, Receptos, Shire, Sigmoid Pharma, Takeda, Topivert, UCB, VHsquared, and Vifor Pharma. S.P.L.T. has received speaker fees from Abbvie, Biogen, Ferring, and Takeda. B.L., F.B., C.B., and S.E.P. are employees of Janssen Research and Development LLC. S.B. and M.C. are currently employees of GSK. F.P. has received research support or consultancy fees (unrelated to this work) from Eli Lilly, Janssen, GSK, Medimmune, Compugen and UCB.